CVRx | Barostim logo — CVRx’s Barostim is a breakthrough technology that stimulates...

CVRx | Barostim

CVRx’s Barostim is a breakthrough technology that stimulates the body’s natural baroreflex to treat heart failure

Founded 2001 United States Minneapolis, United States 246 employees Private Equity Total: $390.60M Biotechnology, Health Care +1

General Information

Company Name CVRx | Barostim
Founded Year 2001
Location United States Minneapolis, United States
Employees 246
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with CVRx | Barostim. To contact CVRx | Barostim, visit cvrx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CVRx | Barostim compare?

A PDF of CVRx | Barostim and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CVRx | Barostim soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CVRx | Barostim

CVRx, also known as Barostim, is a publicly listed (NASDAQ: CVRX) medical devices company founded in 2001 and headquartered in Minneapolis, Minnesota. Their flagship product, Barostim™, is a pioneering technology that leverages the body’s natural baroreflex to address heart failure and high blood pressure. The implantable device activates the carotid baroreceptors, prompting the brain to regulate cardiovascular function. The company's last investment round on 07 July 2020 secured a significant $50.00M from a notable group of investors including New Enterprise Associates, Venrock, Gilde Healthcare, Hatteras Venture Partners, Vensana Capital, Treo Ventures, Johnson & Johnson Development Corporation, and Action Potential Venture Capital. As a prescriptive device, Barostim comes with a set of potential benefits and risks outlined on their website. CVRx's commitment to advancing medical technology is underscored by genuine patient testimonials that highlight the device's impact on individual experiences.

Business keywords: implantable technology, high blood pressure treatment, heart failure treatment, baroreflex stimulation, Rheos implantable pulse generator, carotid sinus leads, Minneapolis-based company, NASDAQ-listed, patient stories, cardiovascular function regulation, publicly traded, device programming system, patient testimonials

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $50.00M 8
New Enterprise Associates, Venrock +6
07 Jul 2020
Series G $93.00M 6
New Enterprise Associates, Gilde Healthcare +4
09 Aug 2019
Debt Financing $20.00M 1
Oxford Finance LLC
09 Aug 2016
Debt Financing $15.00M 1
Silicon Valley Bank
22 Sep 2014
Series F $12.00M 2
DaVita, Ysios Capital
30 Oct 2013
Series F $29.60M 4
New Enterprise Associates, Sight Line Partners +2
10 Jul 2013
Series E $84.00M 7
New Enterprise Associates, InterWest Partners +5
30 Jul 2008
Series D $65.00M 8
New Enterprise Associates, InterWest Partners +6
10 May 2007
Series B $22.00M -
27 May 2003

CVRx | Barostim Alternatives & Competitors

View All Alternatives
CVRx | Barostim vs
medmix
medmix Switzerland

– medmix is a global leader in high-precision delivery devices across healthcare, consumer and indus...

1005 employees
Health Care, Manufacturing
CVRx | Barostim vs
Impulse Dynamics
Impulse Dynamics United States

A cardiac medical device company determined to improve the lives of heart failure patients through C...

Venture round
239 employees
Biotechnology, Health Care
CVRx | Barostim vs
Cytokinetics
Cytokinetics United States

Empowering Muscle Empowering Lives

IPO
779 employees
Biopharma, Biotechnology

FAQ About CVRx | Barostim

CVRx’s Barostim is a breakthrough technology that stimulates the body’s natural baroreflex to treat heart failure
CVRx | Barostim was founded in 2001.
CVRx | Barostim is headquartered in Minneapolis, United States.
CVRx | Barostim operates in Biotechnology, Health Care and Medical Devices. Its work centres on implantable technology, high blood pressure treatment, heart failure treatment and baroreflex stimulation.
CVRx | Barostim has approximately 246 employees.
CVRx | Barostim has completed 9 funding rounds, raising a total of $390.60M. The latest funding stage is Private Equity.
Top alternatives and competitors to CVRx | Barostim include medmix, Impulse Dynamics, Cytokinetics, ONWARD Medical, Edwards Lifesciences IHFM. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CVRx | Barostim and medmix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CVRx | Barostim, https://bouncewatch.com/company/cvrx-barostim, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes